Home
Uncategorized
Towards a Machine Learning Empowered Prognostic Model for Predicting Disease Progression for Amyotrophic Lateral Sclerosis
Uncategorized

Towards a Machine Learning Empowered Prognostic Model for Predicting Disease Progression for Amyotrophic Lateral Sclerosis

No Comments



. 2024 Jan 11:2023:718-725.


eCollection 2023.

Affiliations

Item in Clipboard

Hamza Turabieh et al.


AMIA Annu Symp Proc.


.

Abstract

Amyotrophic lateral sclerosis (ALS) is a rare and devastating neurodegenerative disorder that is highly heterogeneous and invariably fatal. Due to the unpredictable nature of its progression, accurate tools and algorithms are needed to predict disease progression and improve patient care. To address this need, we developed and compared an extensive set of screener-learner machine learning models to accurately predict the ALS Function-Rating-Scale (ALSFRS) score reduction between 3 and 12 months, by paring 5 state-of-arts feature selection algorithms with 17 predictive models and 4 ensemble models using the publicly available Pooled Open Access Clinical Trials Database (PRO-ACT). Our experiment showed promising results with the blender-type ensemble model achieving the best prediction accuracy and highest prognostic potential.

PubMed Disclaimer

Figures


Figure 1.



Figure 1.

Raw clinical features and biomarkers in PRO-ACT


Figure 2.



Figure 2.

Experimental Design.


Figure 3.



Figure 3.

ALSFRS slope distributio


Figure 4.



Figure 4.

Selected features from each algorithm.


Figure 6.



Figure 6.

Kaplan-Meier curves for predicted fast and slow progressor based individual gbr model.


Figure 8a.



Figure 8a.

SHAP value for gbr model with selected features from Boruta algorithm.


Figure 8b.



Figure 8b.

SHAP Value analysis for the small blend ensemble model.

References

    1. Pancotti C., Birolo G., Rollo C., et al. Deep learning methods to predict amyotrophic lateral sclerosis disease progression. Sci Rep. 2022;12:13738. doi: 10.1038/s41598-022-17805-9.

      –

      DOI

      –

      PMC

      –

      PubMed

    1. Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, et al. Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS? Neurotherapeutics. 2015;12(2):417–23. PubMed Central PMCID: PMCPMC4404433. pmid:25613183.

      –

      PMC

      –

      PubMed

    1. Küffner R., Zach N., Norel R., et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51–57. https://doi.org/10.1038/nbt.3051. www.ALSDatabase.org. Accessed: March-19-2023.

      –

      DOI

      –

      PubMed

    1. Sarah Nogueira and Konstantinos Sechidis and Gavin Brown, On the Stability of Feature Selection Algorithms. Journal of Machine Learning Research. 2018;18(174):1–54.

    1. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;3:CD001447.

      –

      PMC

      –

      PubMed

MeSH terms



Source link

You may also like

About The Author

AIGumbo.crew

Leave a Reply

Your email address will not be published. Required fields are marked *